CU20200084A7 - Derivados sustituidos de la carboxamida dihidropirazolo pirazina - Google Patents

Derivados sustituidos de la carboxamida dihidropirazolo pirazina

Info

Publication number
CU20200084A7
CU20200084A7 CU2020000084A CU20200084A CU20200084A7 CU 20200084 A7 CU20200084 A7 CU 20200084A7 CU 2020000084 A CU2020000084 A CU 2020000084A CU 20200084 A CU20200084 A CU 20200084A CU 20200084 A7 CU20200084 A7 CU 20200084A7
Authority
CU
Cuba
Prior art keywords
dihydropirazolo
pirazine
carboxamide
substitute derivatives
substitute
Prior art date
Application number
CU2020000084A
Other languages
English (en)
Inventor
Thomas Brumby
Anja Buchmuller
Alexander Ehmann
Markus Follmann
Xiang Gao
Fabienne Gaugaz
Christoph Gerdes
Michael Gerisch
Nunez Eloisa Jimenez
Elisabeth Kerten
Dieter Lang
Lutz Lehmann
Niels Lindner
Steffen Muller
Hernández Nuria Ortega
Elisabeth Pook
Martina Schafer
Karl-Heinz Schlemmer
Georg Schmidt
Rudolf Schohe-Loop
Frank Sussmeier
Andreas Timmermann
Vivian Wang
Yafeng Wang
Stefanie Zimmermann
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of CU20200084A7 publication Critical patent/CU20200084A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<p>La invención se refiere a un compuesto de la fórmula (I)</p> <p>ESPACIO PARA FÓRMULA</p> <p>útil para preparar medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular de trastornos cardiovasculares, preferentemente de trastornos trombóticos o tromboembólicos y diabetes y también de trastornos urogenitales y oftálmicos.</p> <p>Se refiere también al método de preparación de dicho compuesto.</p>
CU2020000084A 2018-05-17 2019-05-10 Derivados sustituidos de la carboxamida dihidropirazolo pirazina CU20200084A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018087249 2018-05-17
PCT/EP2019/062005 WO2019219517A1 (en) 2018-05-17 2019-05-10 Substituted dihydropyrazolo pyrazine carboxamide derivatives

Publications (1)

Publication Number Publication Date
CU20200084A7 true CU20200084A7 (es) 2021-06-08

Family

ID=66625151

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000084A CU20200084A7 (es) 2018-05-17 2019-05-10 Derivados sustituidos de la carboxamida dihidropirazolo pirazina

Country Status (25)

Country Link
US (1) US20220324865A1 (es)
EP (1) EP3793559A1 (es)
JP (1) JP2021523910A (es)
KR (1) KR20210013084A (es)
CN (1) CN112469412A (es)
AR (1) AR114906A1 (es)
AU (1) AU2019270142A1 (es)
BR (1) BR112020021612A2 (es)
CA (1) CA3100221A1 (es)
CL (1) CL2020002974A1 (es)
CO (1) CO2020014201A2 (es)
CR (1) CR20200554A (es)
CU (1) CU20200084A7 (es)
EA (1) EA202092779A1 (es)
EC (1) ECSP20072258A (es)
JO (1) JOP20200294A1 (es)
MA (1) MA52623A (es)
MX (1) MX2020012201A (es)
NI (1) NI202000083A (es)
PE (1) PE20210856A1 (es)
PH (1) PH12020551973A1 (es)
SG (1) SG11202010679SA (es)
TW (1) TW202012408A (es)
UY (1) UY38237A (es)
WO (1) WO2019219517A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
ES2927104T3 (es) 2016-09-09 2022-11-02 Incyte Corp Derivados de pirazolopiridina como moduladores de HPK1 y usos de los mismos para el tratamiento del cáncer
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
LT3755703T (lt) 2018-02-20 2022-10-10 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
AU2020326703A1 (en) 2019-08-06 2022-02-17 Incyte Corporation Solid forms of an HPK1 inhibitor
WO2021094210A1 (en) * 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094208A1 (en) * 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
CN114236017B (zh) * 2022-02-23 2022-06-07 深圳市海滨制药有限公司 一种棕榈酸抗坏血酸酯及其杂质的检测方法
AU2024258924A1 (en) * 2023-04-19 2025-11-27 Bristol-Myers Squibb Company Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1758585A4 (en) * 2004-06-09 2009-07-22 Merck & Co Inc HIV integrase
DE102004054665A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
DE102007032349A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
WO2009023179A2 (en) 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
BRPI0819505A2 (pt) 2007-12-21 2017-04-04 Genentech Inc "composto, composição farmacêutica, método para inibir o crescimento celular anormal e método para tratar uma doença inflamatória"
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
US9187466B2 (en) 2010-02-27 2015-11-17 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
JP6114189B2 (ja) 2010-07-09 2017-04-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 縮合ピリミジンおよびトリアジンならびに心血管障害の処置および／または予防のためのその使用
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
NZ630489A (en) * 2012-03-28 2016-04-29 Merck Patent Gmbh Bicyclic pyrazinone derivatives
MX2015011898A (es) 2013-03-13 2016-05-05 Genentech Inc Compuestos de pirazolo y usos de los mismos.
JP6348582B2 (ja) 2013-10-09 2018-06-27 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
EP3063150B1 (de) * 2013-10-30 2017-11-22 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
US10189843B2 (en) 2014-02-27 2019-01-29 The University Of Tokyo Fused pyrazole derivative having autotaxin inhibitory activity
BR112017009204A2 (pt) 2014-11-03 2018-07-03 Bayer Pharma Aktiengesellschaft Derivados de feniltriazol hidroxialquil- substituído e usos dos mesmos
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
UA119835C2 (uk) 2016-02-24 2019-08-12 Пфайзер Інк. ПОХІДНІ ПІРАЗОЛО[1,5-а]ПІРАЗИН-4-ІЛУ ЯК JAK-ІНГІБІТОРИ

Also Published As

Publication number Publication date
ECSP20072258A (es) 2020-12-31
MA52623A (fr) 2021-03-24
MX2020012201A (es) 2021-01-29
CO2020014201A2 (es) 2021-03-08
UY38237A (es) 2019-11-29
NI202000083A (es) 2021-03-11
JOP20200294A1 (ar) 2020-11-17
US20220324865A1 (en) 2022-10-13
PH12020551973A1 (en) 2021-08-02
BR112020021612A2 (pt) 2021-01-26
CL2020002974A1 (es) 2021-03-05
TW202012408A (zh) 2020-04-01
EA202092779A1 (ru) 2021-02-02
EP3793559A1 (en) 2021-03-24
SG11202010679SA (en) 2020-11-27
AU2019270142A1 (en) 2020-11-12
WO2019219517A1 (en) 2019-11-21
KR20210013084A (ko) 2021-02-03
PE20210856A1 (es) 2021-05-18
CR20200554A (es) 2021-01-12
CA3100221A1 (en) 2019-11-21
CN112469412A (zh) 2021-03-09
AR114906A1 (es) 2020-10-28
JP2021523910A (ja) 2021-09-09

Similar Documents

Publication Publication Date Title
CU20200084A7 (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
CO2018000113A2 (es) Compuestos derivados de 2-(4-fenil-2-oxopiridin-1-(2h)-il)alcanoilamina
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
MX2020007265A (es) Derivados de rapamicina.
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MX388682B (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
EP4635568A3 (en) Compounds, salts thereof and methods for treatment of diseases
PH12015502248B1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
MX2021008002A (es) Sales nuevas y forma polimorfica del acido bempedoico.
MX386256B (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
CL2021001613A1 (es) Derivados de oxopiridina sustituidos
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
EA201792234A1 (ru) Новые соединения пиридиния
MX2020010985A (es) Procedimiento para la preparacion de iloprost.
EA201691465A1 (ru) Средство для лечения сердечно-сосудистых заболеваний
WO2017029642A3 (en) Novel polymorphs of dolutegravir and salts thereof
TH1701002063A (th) ตัวยับยั้งแอลโดสเทอโรนซินเธส
EA201891690A1 (ru) Агонист fxr, представляющий собой производное стероидов
MX2016014692A (es) Polimorfos cristalinos novedosos de derivados de piridina y metodo para producirlos.